Lymphoma Research Foundation gives grants for follicular, mantle cell lymphomas

The Lymphoma Research Foundation (www.lymphoma.org) has just added to its ever-growing and influential research portfolio by awarding in excess of $2 million in grants to the following researchers and research groups investigating various areas of lymphoma:

Follicular Lymphoma

John (Wing) Chan, MD,
Board of Regents of the University of Nebraska Medical Center
Oncogenic mutations in follicular and transformed follicular lymphoma

Laurence Cooper, MD
University of Texas M.D. Anderson Cancer Center
Off-The-Shelf Immunotherapy For Follicular Lymphoma Infusing CD19-Specific T Cells

David Frank, MD, PhD
Dana-Farber Cancer Institute
Identification and Targeting of Transcription Factor Pathways Activated in Follicular Lymphoma

Mantle Cell Lymphoma:

Elias Campo, MD
Institute for Biomedical Research August Pi i Sunyer (Barcelona, Spain)
Identification of Somatic Mutations in Mantle Cell Lymphoma Using Next Generation Sequencing

Samuel Katz, MD, PhD
Dana-Farber Cancer Institute
Reactivating Apoptosis in Mantle Cell Lymphoma by Peptide Replacement of the Tumor Suppressor BIM

Izidore Lossos, MD
Miller School of Medicine of the University of Miami
New Immunotherapeutic Approaches to Mantle Cell Lymphoma

Thomas Tedder, PhD
Duke University Medical Center
Molecular Insights into MCL Immunotherapy

“These grants emphasize the Foundation’s commitment to ensuring that the brightest research minds are able to pursue a cure for each of the specific types of lymphoma,” said Diane Blum, CEO of the Lymphoma Research Foundation. “We remain grateful for our supporters, whose continued confidence in our organization and the LRF mission sustains this important work.”

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap